Total
0
Shares
Nyrada (ASX:NYR) - CEO, James Bonnar - The Market Herald
CEO, James Bonnar
Source: Perth Now
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Medicinal chemistry work by Nyrada (NYR) has revealed two additional, potent drug candidates for its cholesterol-lowering program
  • The company has been working on an in-vivo efficacy study in mice as part of its cholesterol-lowering program, evaluating if Nyrada’s drug NYX-PCSK9i can enhance the efficacy of a statin when co-administered
  • The study has now been expanded to evaluate the efficacy of the two new drug candidates, with study results expected in June
  • Additionally, the company selected a contract research organisation to oversee the preclinical safety and toxicology studies that are necessary before human clinical trials can begin
  • Nyrada shares last traded at 32 cents on Tuesday, May 4

Medicinal chemistry work by Nyrada (NYR) has revealed two additional, more potent drug candidates for its cholesterol-lowering program.

The ASX-lister is a pre-clinical stage, drug development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases.

The company has been working on an in-vivo efficacy study in mice as part of its cholesterol-lowering program. The program is evaluating whether Nyrada’s drug NYX-PCSK9i can enhance the efficacy of a statin when co-administered.

The company’s recent medicinal chemistry work revealed two promising drug candidates, with testing confirming higher levels of potency and absorption, compared to NYX-PCSK9i.

As a result, the high cholesterol mouse study has now been expanded to evaluate the efficacy of the two new drug candidates.

Results from this study are expected in June, enabling Nyrada to select the optimum drug candidate to take forward into preclinical safety and toxicology testing.

Additionally, the company has selected a contract research organisation to oversee the preclinical safety and toxicology studies that are necessary before human clinical trials can begin. These studies focus on cardiac, central nervous system and respiratory safety while measuring toxicological effects in two animal species — a requirement before starting clinical trials in humans.

The start date of the preclinical safety and toxicology studies depends on having sufficient amounts of the clinical candidate available. Nyrada has been optimising the route of synthesis for these compounds, scaling up its resources from gram to kilogram quantities.

Nyrada shares last traded at 32 cents on Tuesday, May 4.

NYR by the numbers
More From The Market Herald
Healthia (ASX:HLA) to purchase The Eyecare Place

" Healthia (ASX:HLA) to purchase The Eyecare Place

Healthia (HLA) has entered into agreements to purchase The Eyecare Place, an optical store located in Abbotsford, Victoria.
Avita Therapeutics (ASX:AVH) - CEO, Dr Michael Perry - The Market Herald

" Avita Medical (ASX:AVH) reports solid revenue growth over March quarter

Avita Medical (AVH) reported a 126-per-cent revenue increase and steady growth in procedural volumes in its review of the March quarter.
Creso Pharma (ASX:CPH) - Non Executive Chairman, Adam Blumenthal - The Market Herald

" Creso Pharma’s (ASX:CPH) Halucenex secures additional 10 grams of psilocybin

Creso Pharma’s (CPH) target acquisition company Halucenex Life Sciences has secured an additional 10 grams of synthetic psilocybin.
Advanced Human Imaging (ASX:AHI) - CEO Vlado Bosanac - The Market Herald

" Advanced Human Imaging (ASX:AHI) signs agreement with e-Mersion Media

Healthcare stock Advanced Human Imaging (AHI) has signed a binding terms sheet with Melbourne business e-Mersion Media.